VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

October 19, 2017

Study Completion Date

October 19, 2017

Conditions
Refractory or Recurrent Solid Tumors, Excluding CNS Tumors
Interventions
DRUG

Axitinib

Trial Locations (21)

10032

Columbia University Medical Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

Childrens Hospital of Philadelphia, Philadelphia

20010

Children's National Medical Center, Washington D.C.

20892

Mark O Hatfield-Warren Grant Magnusun Clinical Center, Bethesda

30322

Children's Healthcare of Atlanta - Egleston, Atlanta

35233

Children's Hospital of Alabama, Birmingham

38105

St. Jude Children's Research Hospital, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children, Indianapolis

48108

C S Mott Children's Hospital, Ann Arbor

53226

Midwest Children's Cancer Center, Milwaukee

55455

University of Minnesota Cancer Center-Fairview, Minneapolis

60611

Ann and Robert H Lurie Children's Hospital of Chicago, Chicago

63110

Washington University School of Medicine, St Louis

77030

Baylor College of Medicine, Houston

92868

Childrens Hospital of Orange County, Orange

94143

UCSF Medical Center-Parnassus, San Francisco

97239

Oregon Health and Science University, Portland

98145

Seattle Children's Hospital, Seattle

M5G 1X8

Hospital for Sick Children, Toronto

All Listed Sponsors
lead

Children's Oncology Group

NETWORK

NCT02164838 - VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors | Biotech Hunter | Biotech Hunter